Literature DB >> 28869446

bFGF in tumor tissue independently prognosticates disease outcome of a natural course of invasive breast cancer.

Nataša Todorović-Raković, Marko Radulovic, Tijana Vujasinović, Zaki Abu Rabi, Jelena Milovanović, Dragica Nikolić-Vukosavljević.   

Abstract

BACKGROUND: Basic fibroblast growth factor (bFGF) is a potent angiogenic and mitogenic factor that has been functionally predisposed to promote tumorigenesis, while literature data also associate bFGF with a favorable outcome of breast cancer.
OBJECTIVE: In order to help resolve such controversy, this study set out to investigate the role of bFGF in breast cancer for the first time by use of the node-negative patient group with smaller tumors and without any systemic adjuvant therapy. This has allowed an increased homogeneity of the group and a far more reliable interpretation of results.
METHODS: The study included 133 node-negative breast cancer patients with 33 distant metastasis events. bFGF levels were determined by ELISA in primary tumor tissue homogenates.
RESULTS: bFGF in primary tumor tissue associated with favorable breast cancer outcome and its levels significantly and positively correlated with ER levels.
CONCLUSIONS: The obtained results are relevant for the future prognostic research aimed at surpassing the currently achievable prognostic accuracies which are by far inadequate to allow reliable therapeutic decision making in breast cancer.

Entities:  

Keywords:  Breast cancer; bFGF; estrogen receptor; metastasis; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28869446     DOI: 10.3233/CBM-170022

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  1 in total

1.  Angiogenin negatively regulates the expression of basic fibroblast growth factor (bFGF) and inhibits bFGF promoter activity.

Authors:  Jia Zhao; Dezhong Wen; Wenhua Jiang; Jinna Song; Jianli Yang; Xiang Gao; Hui Xue; Li Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.